trending Market Intelligence /marketintelligence/en/news-insights/trending/3cF6UlHr38D1yhJ4IBCuiA2 content esgSubNav
In This List

US FDA expands approval of Horizon treatment to include younger children

Video

S&P Capital IQ Pro | Powering Your Edge

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


US FDA expands approval of Horizon treatment to include younger children

The U.S. Food and Drug Administration expanded the approval of Horizon Pharma Plc's Procysbi to include the treatment of children aged 1 year and above.

The drug, meant to treat a rare metabolic disorder called nephropathic cystinosis, is already approved for the treatment of adults and children as young as two years of age.

The approval was based on the results of a 17-patient study.